Bacterial DNA patterns identified using paired-end Illumina sequencing of 16S rRNA genes from whole blood samples of septic patients in the emergency room and intensive care unit

Monica Martins Pereira Faria 1,5, Brent Warren Winston 2,4,10, Michael Gordon Surette 1,7,8,9 and John Maynard Conly 1,2,3,5,6,10

Abstract

Background: Sepsis refers to clinical presentations ranging from mild body dysfunction to multiple organ failure. These clinical symptoms result from a systemic inflammatory response to pathogenic or potentially pathogenic microorganisms present systemically in the bloodstream. Current clinical diagnostics rely on culture enrichment techniques to identify bloodstream infections. However, a positive result is obtained in a minority of cases thereby limiting our knowledge of sepsis microbiology. Previously, a method of saponin treatment of human whole blood combined with a comprehensive bacterial DNA extraction protocol was developed. The results indicated that viable bacteria could be recovered down to 10 CFU/ml using this method. Paired-end Illumina sequencing of the 16S rRNA gene also indicated that the bacterial DNA extraction method enabled recovery of bacterial DNA from spiked blood. This manuscript outlines the application of this method to whole blood samples collected from patients with the clinical presentation of sepsis.

Results: Blood samples from clinically septic patients were obtained with informed consent. Application of the paired-end Illumina 16S rRNA sequencing to saponin treated blood from intensive care unit (ICU) and emergency department (ED) patients indicated that bacterial DNA was present in whole blood. There were three clusters of bacterial DNA profiles which were distinguished based on the distribution of Streptococcus, Staphylococcus, and Gram-negative DNA. The profiles were examined alongside the patient’s clinical data and indicated molecular profiling patterns from blood samples had good concordance with the primary source of infection.

Conclusions: Overall this study identified common bacterial DNA profiles in the blood of septic patients which were often associated with the patients’ primary source of infection. These results indicated molecular bacterial DNA profiling could be further developed as a tool for clinical diagnostics for bloodstream infections.

Keywords: Sepsis, Illumina, 16 s rDNA sequencing, Molecular profiling, Bloodstream infections

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Sepsis refers to a systemic inflammatory response resulting from pathogenic microorganisms invading normally sterile tissues, fluids or body cavities [1]. It is often triggered by infections which have spread systemically as well as primary bloodstream infections [1]. Although any microbial agent can be implicated in sepsis, over 80% of bloodstream infections are attributed to bacteria [2–6]. The most commonly isolated bacteria from sepsis related bloodstream infections are Staphylococcus aureus, coagulase-negative Staphylococci (CoNS), Enterococcus species, Escherichia coli, and Pseudomonas aeruginosa [3].

Currently, sepsis bloodstream infections are primarily considered as a monomicrobial infection with rare cases of polymicrobial sepsis [7, 8]. However, these results are based on clinical diagnostic blood culture confirmed infections, which currently represents a minority of sepsis cases. We previously described a novel approach of extracting bacterial DNA from saponin-treated whole blood for use in 16S rRNA bacterial DNA analysis with Illumina sequencing [9]. Case study analysis revealed successful application of this novel approach to blood samples from septic patients in the intensive care unit (ICU). In this study, whole blood samples from expanded cohorts of ICU and emergency department (ED) patients presenting with clinical manifestations of sepsis were analyzed. The goal was to determine if molecular sequencing of bacterial DNA in the bloodstream correlated to clinical infection. Bacterial DNA profiles were analyzed alongside relevant blood culture and clinical data. This strengthened the interpretation of the DNA sequencing data as there was good concordance between the principal bacterial DNA recovered and other cultivation based data. This study supports the use of molecular profiling to augment blood culture diagnostics for identification of bacteria involved in bloodstream infections. In addition, the sensitivity of next-generation sequencing also allowed for detection of polymicrobial infections that are likely under-represented using culture-based enrichment methodology.

Methods
Study design
This work was conducted under the aegis of the Alberta Sepsis Network, a multi-year prospective cohort study designed to gather clinical, laboratory, and immunologic data on adult and pediatric patients admitted to the ED or the ICU with a provisional diagnosis of sepsis. Samples were collected from 2010 to 2014 at two hospitals in Calgary, Alberta, Canada. The date on which samples were collected was not provided to protect patient identity. Adult patient enrolment criteria included individuals 18 years or older admitted to the ICU of the Foothills Medical Center who met the published criteria for systemic inflammatory response syndrome (SIRS) and clinical suspicion or confirmation of infection within the first 24 h of admission or within the first 24 h of a newly acquired infection [10, 11]. SIRS criteria included; body temperature > 38 °C or < 36 °C, heart rate > 90/min, evidence of hyperventilation by respiratory rate > 20/min or PaCO2 < 32 mmHg, and white blood cell count > 12,000 cells/μl [11]. At the time of sample collection, the quick sequential organ failure assessment (qSOFA) criteria were not in clinical use [10]. The SOFA score was not regularly collected at the time of sampling, which was prior to the implementation of sepsis-3, but was available for the majority of patients admitted to the ICU [11]. As such, it was not used as an enrolment criterion. Exclusion criteria included patients in which life support care was deemed to be inappropriate. Adult ED patients were enrolled if they were over 18 years of age, and within the first 24 h of admission to the ED, two or more SIRS criteria and clinical suspicion or confirmation of infection. Pediatric ED patients were enrolled at the Alberta Children’s Hospital, Calgary, Alberta if they met the following criteria; under the age of 18, greater than two SIRS criteria present, clinical suspicion or confirmation of infection, and antibiotic treatment ordered for the suspected or confirmed infection and ongoing supportive care was deemed to be appropriate.

Blood was also collected from 12 healthy adults as the final control. These adults were chosen since they would represent the potential for contaminating DNA from the blood collection process including skin-associated bacteria or bacterial DNA present in the sterile vacutainers [12]. The results from these samples were previously reported [9].

Sample collection
Sample collection for this study was done as previously described [9] using agreed upon standard operating procedures. Trained and licensed nurses or phlebotomists collected whole blood and biological samples.

Whole blood samples used for analysis were obtained on Day 1 of ICU admission for sepsis or during presentation to ED with suspected sepsis. Based on the ASN guidelines for blood collection, a maximum of 4 ml of blood and 2 ml of blood were collected from adult and paediatric patients, respectively. Blood was collected from a fresh peripheral venous vascular injection into sterile K2EDTA spray coated vacutainers under aseptic techniques (BD Diagnostics, Mississauga, ON). For patients admitted to the ICU, samples were collected from central arterial or venous lines which were inserted within the first 12 h of ICU admission under aseptic technique [13].
Patient demographics, laboratory and clinical data
Clinical and diagnostic laboratory data was collected following enrolment. Data was considered relevant to the sample if collected within a 24-h period prior to or after enrolment in the study. Clinical data was obtained from the Alberta Sepsis Network database which included patient demographics, admitting diagnosis, APACHE II score [14] and the sepsis-related organ failure assessment (SOFA) score [15]. No ancestry data was collected as it is not part of patient charts in Canada. Each patient was identified only by a unique identifier based on the site in which the sample was obtained; FED samples represented adult ED patient samples, ASN samples represented adult ICU patient samples, ASNC represented adult healthy control samples, and AERG represented pediatric ED patient samples. Clinical laboratory results were collected from Calgary Laboratory Services and included all diagnostic cultures done that were relevant to the patient’s clinical presentation as well as all pharmacy related data for therapy administered.

Saponin treatment and DNA extraction from whole blood
Blood samples noted above were then processed with a custom saponin digestion prior to DNA extraction protocol. Methods for both steps were performed as outlined in Faria et al., (2015) [9]. Briefly, lysis of 1.5 mL of whole blood was achieved using 0.85% saponin (Sigma-Aldrich, USA). Lysed products were removed by centrifugation at 20,800 rcf for 15 min. Remaining cells were washed 3x with 1 ml sterile DNase/RNase free double distilled water (Life Technologies, Burlington, ON, Burlington, ON) [9]. Cells were resuspended in 500 μl sterile PBS for storage prior to DNA extraction. The extraction protocol was outlined in Faria et al., (2015) [9] and included extensive cell lysis using both lysozyme and mutanolysin (Sigma-Aldrich, Oakville, ON), RNaseA treatment (Life Technologies, Burlington, ON), proteinase K treatment (Invitrogen, Life Technologies, Burlington, ON) and DNA separation with phenol-chloroform-isoamyl (Life Technologies, Burlington, ON). Final DNA concentration and purification was done using the Zymo DNA Clean & Concentrator™-25 (Zymo Research, Irvine, CA) column containing 200 μl of ChIP DNA Binding Buffer (Zymo Research, Irvine, CA) [9].

16S rRNA gene bacterial community profiling with paired-end Illumina
Bacterial profiling of the v3 variable region of the 16S rRNA gene was carried out as described previously [9]. The primers used with modifications including the addition of Illumina multiplexing, bridge amplification and sequencing regions were 341F (5’CCTACGGGGA GGCAGCAG3’) and 518R (5’ATTACCGCGGCTTGC TGG3’) [9]. The resulting PCR products were amplified in triplicate as previously outlined [9]. Samples were sequenced using the Illumina MiSeq personal sequencer (Illumina Incorporated, USA) at the McMaster Genomics Facility (Hamilton, ON, Canada) and image analysis, base calling, and error estimation were completed using the Illumina Analysis Pipeline (version 2.6) [16]. Briefly, pooled DNA libraries were tested with the Agilent BioAnalyzer High Sensitivity DNA chip. qPCR was performed as previously described [9, 17]. The 16S rRNA gene v3 region pools were then sequenced, using previously published primers, in the forward and reverse direction on the Illumina MiSeq instrument [9, 17, 18]. Illumina’s Casava software (version 1.8.2) was used to demultiplex each run [9, 17]. Each illumina run included a no-template control sample as an internal control to ensure there was no contamination. The sequencing data was processed with custom, in-house standardized workflow and Perl scripts [9, 18]. Primer removal and trimming was carried out with Cutadapt [19] and paired-end sequences alignment and quality filtering was carried out using PANDaseq [20]. Chimera, singletons, contamination and human DNA was removed during the data filtering steps. The “noRoot” OTU was removed as it represented non-bacterial DNA amplification due to well document 16S primer cross-reactivity to human DNA [21]. Please refer to Additional file 1: Table S1 for OTUs removed during filtering. Following filtering of these sequences, a cut-off of 500 reads per sample was applied as the lowest level of abundance required for analysis.

Taxonomic identification and diversity measures
Taxonomic summaries and subsequent analysis were done using QIIME version 1.7.0 [22]. Operational taxonomic units (OTUs) clustering and analysis of taxonomic summaries was done as previously described [9]. Briefly, operational taxonomic units (OTUs) clustering at a threshold of 97% sequence similarity was carried out using AbundantOTU+ [23]. Taxonomic identification was assigned using the Ribosomal Database Project classifier [24] using the Greengenes reference database, February 4th 2011 release [25] as a training set. QIIME computational analysis pipeline was used for community analysis [22]. Beta-diversity was used to examine variation between DNA profiles from different samples. Both weighted and unweighted UniFrac distances were used for clustering of the samples which were visualised using principal coordinate analysis (PCoA) [26, 27]. KiNG version 2.21 visualization software was used for PCoA plots [28]. Composite unweighted pair group method with arithmetic mean (UPGMA) hierarchical clustering of the sequencing data was done with weighted UniFrac distance metrics. Jackknife beta-diversity on evenly re-sampled OTU tables was applied using
weighted UniFrac distance to validate the strength of UPGMA clustering [26].

The representative sequence for each OTU was also aligned to 16S rRNA sequences using the HOMD database (www.homd.org) and to the National Center for Biotechnology-Basic Local Alignment Search Tool (NCBI-BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi) megalast nucleotide search tool.

In addition, PCR and illumina sequencing was performed on all the reagents and buffers used in the saponin blood-treatment and the DNA extraction protocol. These results were previously discussed [9].

Results
Patient demographics and admission results
Based on sequencing criteria discussed in the next section, not all patient blood samples processed were included in the analysis. Of the 52 ED blood samples collected, 12 were analyzed (mean age 50 years (± 13.18 SD). The predicted sources of infection were lung (4/12), genitourinary (2/12), skin soft-tissue (2/12), joint/bone (1/12), endovascular (2/12), and one unknown (Table 1). From the pediatric ED blood samples cohort, 9 of 28 samples were analyzed (mean age = 4 years (± 2.87 SD). The predicted sources of sepsis were pneumonia (3/9), intra-abdominal infection (3/9), meningitis (1/9), and two unknown (Table 1). A positive blood culture was identified in 67% of the adult ED patients and in 11% of the pediatric ED patients included in this study (Table 1). The healthy blood samples came from healthy adults and were discussed previously [9].

Of the 116 ICU patient blood samples collected, 54 were used for analysis based on parameters for DNA sequencing depth outlined in a subsequent section. The clinical data upon ICU admission for the 54 patient samples used included the patients’ age, sex, APACHE II score, SOFA score, the ICU length of stay (LOS), and outcome (Table 2). Summary statistics of clinical parameters for ICU patients is available in Additional file 2: Table S2. Briefly, the mean age was 58 years (SD 15.62) with 51.9% of patients being male. The average admitting APACHE II score, a measure of disease severity [14], was 22.9 (SD 7.1). The SOFA score, a measure of organ failure [15], average was 10 (SD 4.1). With respect to mortality, 9 of 54 (17%) died during their admission. The principal sources of infection were lower respiratory tract infections n = 18 (33%) patients and gastrointestinal infections n = 16 (30%); there were n = 4 (7%) who had septic shock. A positive blood culture result was present in 30% of the ICU patients included in this study.

Bacterial DNA profiles of blood of septic ICU patients clustered into three groups
Prior to analysis, sequencing data was filtered to remove low diversity samples. After this the counts per sample were a minimum of 151, maximum of 41,7190 with a median of 1795.5 and mean count per sample of 14,725. Following the removal of the “noRoot” OTU, singletons, and known contaminant OTUs, the number of counts per sample decreased (Table 3). The OTUs removed from the analysis are available in Additional file 2: Table S2.

Phylogenetic relationships in the ICU patient samples with at least 500 sequences were analyzed. Beta-diversity was assessed using jackknife analysis equally resampled OTU tables to ensure clustering was consistent [27]. Hierarchical clustering based on UniFrac was visualized as UPGMA phylogenetic trees, a well supported method for visualization of next-generation sequencing data [9, 17, 18, 22]. Due to low sequencing depth, 62 patient samples were not clustered. The taxonomic profiles of the remaining 54 patients (of the original 116) samples with a sequencing depth above 500 were clustered into three main groups (Fig. 1a). As indicated, the “noRoot” OTU was removed from analysis as it represented human DNA. When the “noRoot” OTU sequence was aligned in the NCBI-BLAST database the alignments were to mitochondrial DNA or to eukaryotic sequences. The proportion of non-bacterial “noRoot” OTU in the septic blood samples ranged from 99.98 to 0.007% with the average being 92.4% (Table 3).

For the 54 samples used in the analysis, the sequences per sample ranged from a minimum number of sequences per sample of one and a maximum of 166,596. OTUs that were detected less than 10 times in the population were excluded resulting in 460,386 sequences representing 355 OTUs. These OTUs clustered into 141 taxonomically distinct groups with the reference sequence reflecting the maximum level in which the RDP Classifier would, with confidence, identify the OTU [24].

Three clusters of DNA profiles were identified in the ICU sample cohort (Fig. 1a). Group 1 OTU profiles were distinguished by the abundance of Streptococcus DNA with two clades. The Group 1A samples had 65% or higher relative abundance of Streptococcus and the Group 1B samples with less than 65% but greater than 30% Streptococcus DNA (Fig. 1b). Using the representative sequence for each dominate OTU, further classification of the Streptococcus was predicted. Four of the patients had species of Streptococcus Mitis Group (S. pneumoniae/mitis/oralis) as the principal OTU, four had the Streptococcus Anginosus/Milleri “group” as the principal OTU, one had a Streptococcus dysgalactiae/agalactiae OTU, and an additional three had a similar abundance of a Streptococcus Mitis Group OTU and Staphylococcus aureus OTUs, and one patient had similar abundance of the Streptococcus Anginosus/Milleri OTU and the Streptococcus Mitis Group (Table 3).

Group 2 ICU patient blood samples had the greatest diversity in terms of taxonomic representation (Fig. 1a).
A unifying trend for Group 2 was abundance of OTUs representing Gram-negative bacteria (Fig. 1b). Group 2 was further subdivided into two clades with Group 2A having four sub-groups I, II, III, and IV (Fig. 1b). In Group 2AI, most DNA diversity was represented by the Gammaproteobacteria, Proteobacteria, and Pseudomonas taxonomic groups in the first clade whereas Group 2AII were represented by the Enterobacteriaceae and Klebsiella DNA (Table 3). Within Group 2AI, there was one blood sample in which the Serratia taxon represented 100% of the relative DNA abundance (Fig. 1b). There was only one Serratia OTU present in the SB samples and the representative sequence aligned to the Serratia marcescens 16S rRNA gene (Table 3). There was also one sample in Group 2AI, ASN438, in which Legionella DNA represented 25% of the relative DNA abundance. This was the only ICU patient where Legionella DNA was recovered (Fig. 1b). The Group 2AII samples had greater taxonomic diversity and the principal OTUs identified in the Group 2AII samples had sequence identities matching Bacillus, Gammaproteobacteria, Lachnospiraceae, Xanthomonadaceae, and Staphylococcus (Table 3). The Group 2AIII isolates had a mix of OTUs representing both Gram-positive and Gram-negative bacteria in equal proportions (Fig. 1a-b). Group 2AIV consisted of one patient blood sample in which the abundance of the Prevotella DNA, at 30%, separated in from the other Group 2 samples (Fig. 1b). The Group 2B was also represented by a single sample where Finegoldia DNA represented 76% of the OTU abundance (Fig. 1b). The Finegoldia OTU aligned to Finegoldia magna (Table 3).

The third cluster of ICU blood samples grouped based on the Staphylococcus DNA abundance (Fig. 1a). Group 3A consisted of blood samples in which Staphylococcus represented 37–75% of the bacterial DNA amplified (Fig. 1a). The majority of samples had a Staphylococcus OTU.

### Table 1
Demographics of samples collected from adult ED (FED) patients and samples collected from pediatric ED (AERG) patients

| Patient     | Age Range | Gender | SIRS (1–4) | Primary Focus of Infection | Blood Culture | Top OTU(s)                        |
|-------------|-----------|--------|------------|-----------------------------|---------------|-----------------------------------|
| **Adult ED Samples**                                   |           |         |            |                             |               |                                   |
| FED31       | 30–40     | M       | 2          | Endovascular                | Negative      | Anaerococcus, Staphylococcus      |
| FED56       | 70–80     | M       | 4          | Skin or soft tissue         | Unknown       | Bacillaceae                       |
| FED7        | 30–40     | M       | 4          | Catheter related            | Staphylococcus aureus | Staphylococcus                   |
| FED36       | 50–60     | M       | 4          | Endovascular                | Serratia marcescens | Serratia                           |
| FED14       | 40–50     | F       | 3          | Skin or soft tissue         | Staphylococcus aureus | Streptococcus, Gammaproteobacteria |
| FED42       | 50–60     | M       | 2          | Lung                        | Streptococcus pneumoniae | Escherichia, Gammaproteobacteria |
| FED39       | 60–70     | F       | 3          | Unknown                     | Group B Streptococcus | Escherichia, Streptococcus        |
| FED44       | 40–50     | F       | 2          | Lung                        | Streptococcus pneumoniae | Enterobacteriaceae, Klebsiella   |
| FED15       | 60–70     | M       | 2          | Bone/Joint                  | Negative      | Streptococcus, Bacillus           |
| FED4        | 40–50     | F       | 4          | Urinary Tract               | Escherichia coli | Gammaproteobacteria               |
| FED57       | 40–50     | F       | 3          | Lung                        | Unknown       | Streptococcus, Actinomycetales    |
| FED34       | 40–50     | M       | 3          | Lung                        | Streptococcus pneumoniae | Lactococcus, Streptococcus        |
| **Pediatric ED Samples**                               |           |         |            |                             |               |                                   |
| AERG2.106   | 2–3       | F       | 2          | Pneumonia                   | Negative      | Streptococcus, Escherichia,       |
|             |           |         |            |                             |               | Staphylococcus                    |
| AERG2.102   | 4–5       | F       | 3          | Appendicitis                | Negative      | Staphylococcus, Streptococcus     |
| AERG2.113   | 4–5       | F       | 3          | Meningitis                  | Negative      | Staphylococcus, Streptococcus     |
| AERG1.106   | 2–3       | F       | 2          | Pneumonia                   | Negative      | Enterobacteriaceae, Streptococcus |
| AERG2.043   | 7–8       | F       | 2          | Appendicitis                | Negative      | Staphylococcus                    |
| AERG2.076   | 10–11     | F       | 2          | Duplicate Cyst              | Negative      | Staphylococcus                    |
| AERG2.205   | 2–3       | M       | 2          | Pneumonia                   | Gram-positive cocci resembling Staphylococcus | Bacillaceae, Staphylococcus, Moraxella, Enterococcus, Clostridium |
| AERG2.235   | No data   | No data | No data    | No data                     | Negative      | Bacillaceae, Staphylococcus, Moraxella, Enterococcus, Clostridium |
| AERG2.198   | 3–4       | F       | 4          | No data                     | Negative      | Bacillaceae, Staphylococcus, Moraxella, Enterococcus, Clostridium |

Faria et al. BMC Microbiology (2018) 18:79
| Sample | Age Range | Gender | Admitted From | Admitting Diagnosis | Admitting APACHE II | Max SOFA | ICU Outcome |
|--------|-----------|--------|---------------|---------------------|---------------------|----------|-------------|
| Group 1-A | | | | | | | |
| ASN455 | 40–50 | F | In-patient | Sepsis-Unknown | 29 | 17 | Dead |
| ASN350 | 40–50 | M | Other | Bacterial pneumonia | 19 | 18 | Dead |
| ASN449 | 60–70 | F | In-patient | Intracranial abscess | 26 | 8 | Alive |
| ASN452 | 70–80 | M | ED | Bacterial pneumonia | 13 | 5 | Alive |
| ASN469 | 60–70 | M | OR | Surgery for cellulitis | 27 | 10 | Alive |
| ASN470 | 60–70 | M | In-patient | Sepsis-Gastrointestinal | 34 | 17 | Dead |
| ASN465 | 70–80 | F | In-patient | Cardiac arrest, post-kidney transplant | 28 | 12 | Alive |
| ASN463 | 70–80 | F | In-patient | Congestive heart failure | 28 | 7 | Alive |
| Group 1-B | | | | | | | |
| ASN366 | 50–60 | M | OR-Emergency | Tonsill or pharyngeal infection | 19 | 10 | Alive |
| ASN357 | 80–90 | F | Other | Septic shock | 28 | 8 | Alive |
| ASN376 | 20–30 | M | OR-Emergency | Haemothorax or haemopneumothorax | 20 | 7 | Alive |
| ASN368 | 60–70 | M | OR-Emergency | Leaking biliary anastamosis | 11 | 7 | Alive |
| ASN294 | 60–70 | F | Other | Self poisoning with sedatives or hypnotics | 10 | 8 | Alive |
| Group 2-Al | | | | | | | |
| ASN167 | 30–40 | F | ED | Hepatic abscess | 15 | 5 | Alive |
| ASN168 | 50–60 | F | In-patient | Bacterial pneumonia | 31 | 11 | Alive |
| ASN475 | 70–80 | F | In-patient | Gastrointestinal abscess | 18 | 7 | Alive |
| ASN438 | 50–60 | F | ED | Pneumonia-Other | 21 | 6 | Alive |
| ASN429 | 70–80 | F | In-patient | Respiratory cause | 16 | 10 | Alive |
| ASN315 | 20–30 | M | OR-Emergency | Necrotizing fasciitis and septic shock | 7 | 5 | Alive |
| ASN363 | 30–40 | M | ED | Septic shock | 16 | 12 | Alive |
| Group 2-AII | | | | | | | |
| ASN338 | 20–30 | M | OR-Emergency | Traumatic rupture or laceration of liver | 30 | 15 | Alive |
| ASN300 | 60–70 | F | OR-Emergency | Small bowel infarction | 24 | 16 | Alive |
| ASN292 | 60–70 | M | OR-Emergency | Septic shock | 34 | 16 | Alive |
| ASN297 | 50–60 | F | OR-Emergency | Oesophageal or gastro-oesophageal tumour | 24 | 10 | Alive |
| ASN328 | 20–30 | M | ED | Self poisoning with narcotics | 22 | 11 | Alive |
| ASN473 | 70–80 | M | ED | Bacterial pneumonia | 32 | 11 | Dead |
| ASN420 | 50–60 | F | ED | Bacterial pneumonia | 10 | 6 | Alive |
| Group 2-AIII | | | | | | | |
| ASN379 | 70–80 | M | In-patient | Pneumonia | 28 | 12 | Alive |
Table 2 Admissions data for the adult ICU patients in Groups 1–3 (Continued)

| Sample | Age Range | Gender | Admitted From | Admitting Diagnosis | Admitting APACHE II | Max SOFA | ICU Outcome |
|--------|-----------|--------|---------------|---------------------|---------------------|----------|-------------|
| ASN371 | 50–60 M   | Other  | Other         | Bleeding duodenal ulcer | 21                  | 1        | Alive       |
| ASN381 | 50–60 F   | OR-Emergency | Bacterial pneumonia | 16                  | 4        | Alive       |
| ASN432 | 50–60 F   | ED     | Other         | Necrotizing fasciitis and bacterial pneumonia | 20                  | 8        | Alive       |
| ASN444 | 70–80 F   | ED     | Other         | Emphysema/bronchitis | 24                  | 4        | Alive       |
| ASN440 | 60–70 M   | ED     | Other         | Cutaneous cellulitis | 15                  | 12       | Alive       |
| ASN39  | 30–40 M   | In-patient | Intracranial abscess | 23                  | 11       | Alive       |
| ASN43  | 50–60 M   | In-patient | Inhalation pneumonitis (gastrointestinal contents) | 27                  | 8        | Alive       |
| Group 2-AIV |        |        |               |                     |                     |          |             |
| ASN415 | 70–80 F   | ED     | Other         | Pneumonia-Other     | 30                  | 9        | Alive       |
| Group 2-B |        |        |               |                     |                     |          |             |
| ASN479 | 50–60 M   | ED     | Other         | Septic arthritis    | 19                  | 11       | Alive       |
| Group 3-A |        |        |               |                     |                     |          |             |
| ASN458 | 60–70 M   | OR-Emergency | Bacterial pneumonia and cardiovascular surgery | 40                  | 20       | Dead        |
| ASN436 | 70–80 M   | ED     | Other         | Sepsis-Gastrointestinal | 23                  | 8        | Alive       |
| ASN440 | 60–70 F   | In-patient | Congestive heart failure and emphysema/bronchitis | 28                  | 12       | Alive       |
| ASN451 | 70–80 F   | OR-Emergency | Surgery for gastrointestinal perforation/rupture | 27                  | 14       | Alive       |
| ASN409 | 50–60 M   | In-patient | Respiratory cause | 22                  | 10       | Alive       |
| ASN418 | 40–50 F   | ED     | Other         | Surgery for (resection) gastrointestinal vascular ischemia, | 26                  | 10       | Dead        |
| ASN454 | 70–80 M   | ED     | Other         | Upper gastrointestinal bleeding | ND\(^a\)         | 4        | Dead        |
| ASN408 | 40–50 M   | In-patient | Surgery for abdomen-trauma | 15                  | 5        | Alive       |
| ASN434 | 50–60 M   | In-patient | Sepsis-Unknown | 26                  | 12       | Alive       |
| ASN424 | 60–70 M   | In-patient | Surgery for (resection) gastrointestinal vascular ischemia, | 14                  | 12       | Dead        |
| ASN464 | 60–70 M   | OR-Emergency | Surgery for gastrointestinal perforation/rupture | 26                  | 12       | Alive       |
| ASN348 | 70–80 F   | OR-Emergency | Septic shock | 27                  | 12       | Alive       |
| ASN466 | 70–80 F   | In-patient | Surgery for cholecystectomy/cholangitis (gallbladder removal) | 31                  | 9        | Alive       |
| ASN461 | 20–30 M   | ED     | Other         | Bacterial pneumonia | 19                  | 12       | Alive       |
| Group 3-B |        |        |               |                     |                     |          |             |
| ASN476 | 60–70 M   | In-patient | Septic arthritis | 31                  | 9        | Alive       |
| ASN474 | 40–50 F   | In-patient | Sepsis-Pulmonary | 29                  | 19       | Dead        |
| ASN477 | 50–60 M   | ED     | Other         | Bacterial pneumonia | 17                  | 9        | Alive       |

\(^a\)No Data
| Sample | Blood Culture | Other Culture | "noRoot" OTU % | Top OTU(s) | RepresentativeSequenceID |
|--------|---------------|---------------|----------------|------------|--------------------------|
| Group 1-A |               |               |               |            |                          |
| ASN455 | Group G Streptococcus | Group G Streptococcus | 98.8 | 175 | Streptococcus dysgalactiae/agalactiae |
| ASN350 | Negative | Negative | 97.2 | 5 | Streptococcus pneumoniae/oralis/mitis |
| ASN349 | Negative | Streptococcus intermedius | 99.4 | 5 | Streptococcus pneumoniae/oralis/mitis |
| ASN452 | Negative | Not Done | 98.9 | 8 | Streptococcus intermedius/anginosus |
| ASN469 | Campylobacter urelyticus, Fusobacterium species | Enterococcus | 92.8 | 8 | Streptococcus intermedius/anginosus |
| ASN470 | VRE | VRE | 74.8 | 8,5 | Streptococcus intermedius/anginosus, Streptococcus pneumoniae/oralis/mitis |
| ASN465 | Negative | VRE | 95.4 | 8 | Streptococcus intermedius/anginosus |
| ASN463 | Negative | Not Done | 97.4 | 8 | Streptococcus intermedius/anginosus |
| Group 1-B |               |               |               |            |                          |
| ASN366 | Negative | Streptococcus anginosus, Prevotella species, CoNS | 91.9 | 2,5 | Staphylococcus aureus, Streptococcus pneumoniae/oralis/mitis |
| ASN357 | Negative | VRE | 97.8 | 5 | Streptococcus pneumoniae/oralis/mitis |
| ASN376 | Not Done | Not Done | 90.1 | 5,2 | Streptococcus pneumoniae/oralis/mitis, Staphylococcus aureus |
| ASN368 | Negative | Klebsiella pneumoniae, Haemophilus parainfluenzae, Prevotella species | 94.8 | 5,2 | Streptococcus pneumoniae/oralis/mitis, Staphylococcus aureus |
| ASN294 | Staphylococcus aureus | Staphylococcus aureus | 94.9 | 5 | Streptococcus pneumoniae/oralis/mitis |
| Group 2-AI |               |               |               |            |                          |
| ASN167 | Negative | SMG | 94.1 | 32 | Gammaproteobacteria |
| ASN168 | Not Done | Fungal | 96.9 | 32 | Gammaproteobacteria |
| ASN475 | Pseudomonas aeruginosa | Pseudomonas aeruginosa | 98.0 | 15,32,48 | Gammaproteobacteria, Gammaproteobacteria, Pseudomonas sp. |
| ASN438 | Negative | Legionella pneumophila | 98.4 | 3,4379 | Enterobacter sp., Klebsiella sp., Legionella sp. |
| ASN429 | Negative | Legionella pneumophila | 87.1 | 3 | Enterobacter sp. |
| ASN315 | Negative | Not Done | 83.3 | 3 | Enterobacter sp. |
| ASN363 | Staphylococcus aureus, Gram-negative bacilli | Staphylococcus aureus | 0.72 | 11 | Serratia marcescens |
| Group 2-All |               |               |               |            |                          |
| ASN338 | Not Done | Not Done | 96.8 | 2,101 | Staphylococcus aureus, Anaerococcus sp. |
| ASN300 | Negative | Fungal | 92.5 | 32 | Gammaproteobacteria |
| ASN292 | Negative | Not Done | 91.0 | 6,76,125 | Bacillus sp., Lachnospiraceae, Bacillus sp. |
Table 3 Clusters, Clinical Microbiology, and OTU analysis of the adult ICU patient blood samples (Continued)

| Sample  | Blood Culture | Other Culture | "noRoot" OTU % | Top OTU(s) | RepresentativeSequenceID |
|---------|---------------|---------------|----------------|------------|--------------------------|
| ASN297  | Fungal        | Fungal        | 92.1           | 40,15,125, | Streptococcus sp., Proteobacteria, Bacillus sp. |
| ASN328  | Negative      | Staphylococcus aureus, Streptococcus pneumoniae | 94.9 | 2 | Staphylococcus aureus |
| ASN473  | Pseudomonas aeruginosa | Not Done | 92.5 | 15 | Proteobacteria |
| ASN420  | Negative      | Not Done      | 97.5           | 2,59       | Staphylococcus aureus, Proteobacteria |
| ASN379  | Negative      | Not Done      | 77.5           | 2 | Staphylococcus aureus |
| ASN371  | CoNS          | Not Done      | 93.8           | 2,5,13     | Staphylococcus aureus, Streptococcus pneumoniae/oralis/mitis, Escherichia coli |
| ASN381  | Negative      | Legionella pneumophila | 94.0 | 13,3,2 | Escherichia coli, Enterobacter sp., Staphylococcus aureus |
| ASN432  | Negative      | Group A Streptococcus | 95.2 | 8,23 | Streptococcus intermedius/anginosus, Staphylococcus aureus, Enterobacter sp. |
| ASN444  | Negative      | Not Done      | 99.2           | 8,3        | Streptococcus intermedius/anginosus, Enterobacter sp. |
| ASN340  | Group C Streptococcus | Not Done | 99.3 | 2,13 | Staphylococcus aureus, Escherichia coli |
| ASN339  | Negative      | Not Done      | 98.6           | 2,3        | Staphylococcus aureus, Enterobacter sp. |
| ASN343  | Negative      | Fungal        | 99.7           | 2,15       | Staphylococcus aureus, Proteobacteria |
| ASN415  | Negative      | Not Done      | 93.3           | 97         | Prevotella melaninogenica |
| ASN479  | Negative      | Finegoldia magna | 99.2 | 81 | Finegoldia magna |
| ASN458  | MRSA          | MRSA          | 84.2           | 2          | Staphylococcus aureus |
| ASN436  | Negative      | VRE           | 92.5           | 2          | Staphylococcus aureus |
| ASN440  | Enterococcus faecium | Not Done | 97.2 | 2 | Staphylococcus aureus |
| ASN451  | Not Done      | Not Done      | 99.5           | 2          | Staphylococcus aureus |
| ASN409  | Not Done      | Not Done      | 98.6           | 2          | Staphylococcus aureus |
| ASN418  | Not Done      | Not Done      | 87.1           | 2          | Staphylococcus aureus |
| ASN454  | Negative      | Not Done      | 98.4           | 2          | Staphylococcus aureus |
| ASN408  | Not Done      | Not Done      | 80.2           | 2          | Staphylococcus aureus |
| ASN434  | Pseudomonas aeruginosa | Not Done | 8.3 | 2 | Staphylococcus aureus |
| ASN424  | Bifidobacterium species | Not Done | 88.8 | 2 | Staphylococcus aureus |
| Sample | Blood Culture | Other Culture | “noRoot” OTU % | Top OTU(s) | RepresentativeSequenceID |
|--------|---------------|---------------|----------------|------------|--------------------------|
| ASN464 | Not Done      | Not Done      | 76.2           | 2,8,5      | Staphylococcus aureus, Streptococcus pneumoniae/oralis/mitis |
| ASN48  | Negative      | Micrococcus species, Streptococcus viridans group     | 98.2           | 2,5        | Staphylococcus aureus, Streptococcus pneumoniae/oralis/mitis |
| ASN466 | Negative      | CoNS, Coryneform bacilli, Candida parapsilosis        | 92.8           | 2,8,13     | Staphylococcus aureus, Streptococcus intermedius/anginosus, Escherichia coli |
| ASN461 | Fusobacterium necrophorum | Fusobacterium | 90.8           | 2,72       | Staphylococcus aureus, Fusobacterium |
| ASN476 | Escherichia coli | Not Done | 80.2           | 6,2,19     | Bacillus sp., Staphylococcus aureus, Lysinibacillus sp. |
| ASN474 | Negative      | Not Done      | 32.6           | 6,2,17     | Bacillus sp., Staphylococcus aureus, Moraxella sp. |
| ASN477 | Negative      | Not Done      | 96.6           | 6,2,32     | Bacillus sp., Staphylococcus aureus, Gammaproteobacteria |

*Refers to any other clinical diagnostic culture results that pertained to that patient within 24 hours of whole blood collection

*OTU number that represented most sequences identified and aligned in the Illumina analysis

*Results from alignment of the top OTU representative sequence to curated 16S rRNA databases

*Based on composite UPGMA trees generated using weighted UniFrac and jackknife resampling
Fig. 1 Taxonomic profiles of whole blood samples from septic ICU patient. Septic whole blood samples collected from ICU patients clustered into three groups based on their taxonomic bacterial DNA profiles. Taxonomic profiles of whole blood samples with 500 or more sequences and clustered using weighted UniFrac (54 patients). A composite unweighted pair group method with arithmetic mean (UPGMA) tree of all the samples was generated with the profiles ordered based on their placement in the UPGMA tree (a). Three groups of SB samples were clearly identified. Group 1 was defined by the abundance of Streptococcus in the profile, Group 2 by the abundance of Gram-negative OTUs, and Group 3 by the abundance of Staphylococcus. Blood culture results for each sample are indicated below the sample. Blood culture positive but discordant from molecular sequencing are indicated by (+), blood culture positive with concordance to sequencing by (a red +), and blood culture negative (−). Samples with a (*) are those with molecular profile results that are supported by other clinical culture data. The average taxonomic profile for the cluster groups shows the breakdown of the bacterial DNA distribution in each taxonomic cluster group (b).
that aligned to *S. aureus* (Table 3). The Group 3B clade was distinguished from 3A by the *Bacillaceae* and *Moraxella* DNA representing 25–41% and 5–14% of the molecular profiles (Fig. 1b). This was also the only group in which *Clostridium* and *Enterococcus* DNA were amplified to a detectable level in the taxonomic profiles (Fig. 1a).

Lastly, the 62 low sequence depth samples were assessed. Principal coordinates analysis (PCoA) done on low sequence depth SB samples indicated that the majority of the low sequence depth samples aligned with the three clusters of ICU patient blood samples analyzed with 12 outliers detected (Fig. 2).

**Correlation of bacterial DNA profiles to clinical microbiology data from septic ICU patients**

The conventional blood culture results for the ICU patients were compared to the molecular profiles obtained in this study (Table 3). Of the 54 patients clustered, blood culture results were obtained for 46 patients with only 15 (33%) having a positive blood culture result. There was limited concordance between molecular profiling and blood culture data which was present in 5 samples (Fig. 1a). In contrast, concordance between molecular profiles and primary infection sample results was noted in several cases discussed below.

The blood sample from ASN455 had *Streptococcus* DNA representing over 75% of the bacterial DNA amplified (Table 3). The representative sequence ID for the *Streptococcus* OTU in this sample aligned to *S. agalactiae/dysgalactiae*, which are typically Group G *Streptococcus* [29]. This correlated with the clinical blood culture results which indicated Group G *Streptococcus* was cultivated (Table 3).

In the ASN363 sample, the *Serratia* OTU represented 100% of the relative DNA abundance (Table 3) whereas diagnostic blood culture indicated a *S. aureus* infection with Gram-negative bacilli (Table 2). Given the molecular profiling data, it could be hypothesized that the Gram-negative bacilli that failed to grow were *S. marcescens*.
ASN438 was a blood sample from a patient who was known to have a *L. pneumophila* pneumonia as part of the documented *Legionella* outbreak within the Calgary Health Region in November–December of 2012. Pleural fluid culture results for this patient were positive for *L. pneumophila* empyema yet blood culture was negative (Table 3). However, the molecular profiling data included the *Legionella* OTU providing evidence that *L. pneumophila* was likely in the bloodstream but below the threshold level to be recovered by blood culture diagnostics.

Patient ASN479 in which clinical diagnostic blood cultures were negative yet the *Finegoldia* OTU was identified in molecular profiling of their blood sample. Given the presence of *F. magna* cultured from the patient's septic joint fluid, the molecular profiling data was suggestive of a *F. magna* bloodstream infection (Table 3).

Lastly, ASN458 patient had MRSA identified from blood culture as well as their predicted primary infection sample (Table 3). The molecular profiling of the ASN458 blood sample indicated the principal OTU had sequence alignment to *S. aureus* indicating a correlation between the molecular profiling results and the clinical culture data.

Overall, these cases highlighted how next-generation sequencing of DNA from septic patients could be used to detect clinically significant infections as the results correlated with the clinical data. A unifying trend was the implication of haematogenous spread of bacteria from the primary infection sources into blood even if blood cultures were negative.

**Bacterial DNA profiles from septic blood were distinct from healthy controls**

Prior to applying this method to clinical samples, intense analysis was done to ensure bacterial DNA recovered was not a result of contamination [9]. As reported previously, DNA profiles obtained from healthy adult blood samples clustered separately from blood samples from healthy adult blood samples clustered together and were phylogenetically distinct from the bacterial DNA profiles identified in blood samples from septic ICU patients. A composite unweighted pair group method with arithmetic mean (UPGMA) phylogeny of all the samples was generated with from the jackknife, weighted UniFrac beta-diversity comparison of the DNA profiles from septic ICU patient samples and healthy adult blood samples. The ICU adult blood samples were labeled based on the cluster groups identified in Fig. 1.

The taxonomic cluster group's 1A, 1B, 2AI, 2AII, 2AIV, 3A, and 3B remained intact when clustered with healthy adult blood samples. The DNA profiles from healthy adult blood samples clustered together and were a distinct clade which divided the Group 2AIII cluster. Despite this, the addition of the healthy adult blood samples did not impact the tree structure as the distribution of all three clusters of bacterial DNA profiles from septic ICU patient samples was preserved.
septic ICU patients [9]. Further, the addition of the healthy blood samples to the analysis did not impact the phylogenetic tree structure distribution for cluster Group 1 or Group 3 (Fig. 3). Based on this, the bacterial DNA profiles in these groups were considered as potential bloodstream infections and not contamination. For Group 2, clusters remained intact in terms of the distribution of samples and the branching within the tree except for Group 2AIII. These samples were distinguished from the healthy control samples by the prevalence of certain OTUs including *Fusobacterium*, *Neisseria*, and *Anaerococcus* in the last three patients (Fig. 3). The Group 2AIII blood samples were statistically distinct from the healthy blood samples in phenetic diversity based on weighted UniFrac (PERMANOVA, *p* = 0.001) [9]. Despite this, the clustering of their molecular profiles with the control samples limited interpretation of the DNA profiles. These patients perhaps had lower bacterial DNA abundance in the sample thereby increasing the relative abundance of the contaminants in the taxonomic profile. Caution was used in the interpretation of the data such that OTU prevalence was considered significant when there was supporting clinical information.

Common bacterial DNA patterns existed across adult and pediatric sepsis patients from the ED

In addition to the septic patients from the ICU, blood samples were also collected from adult and pediatric patients presenting in the Emergency Department (ED) that were suspected of sepsis. Twelve of these were analyzed further. The rationale was to determine if these ED patients had bacterial DNA profiles similar those patients admitted to ICU with clinically confirmed sepsis. The bacterial profiles from the ED patients cluster with the ICU samples into the groups described in Fig. 1 and distinct from the healthy controls (Fig. 4). As seen with the ICU patient cohort, the clusters were defined by abundance of *Streptococcus* OTUs, Gram-negative OTUs, or *Staphylococcus* OTUs. Nine ED sample profiles clustered with the Gram-negative dominant samples whereas two ED samples grouped with the *Staphylococcus* and one ED sample grouped with the *Streptococcus* dominant samples, respectively (Fig. 4).

**Discussion**

The use of Illumina sequencing technology combined with a novel DNA recovery method enabled the characterization of bacterial DNA isolated from 3 to 5 ml blood samples collected from several cohorts of
septic patients. Among these cohorts, the samples from patients admitted to ICU with sepsis had the highest number of samples available to examine trends. Analysis of the bacterial DNA profiles, presented as a proportion of total bacterial DNA, indicated that three common distributions were present in these samples. Association with the infection source, based on the admission diagnosis, showed the strongest correlation to the bacterial DNA profiles. The Group 1 bacterial DNA profile had OTUs representative of commensal microbiota from the upper respiratory tract or the skin in addition to Streptococcus as the predicted pathogen (Fig. 1, Table 2). Many of the patients in Group 1 were admitted with pneumonia, upper respiratory tract infections, abscess and cellulitis. Streptococcus species are recognized principal pathogens in these clinical presentations [29–35]. The Group 2 patients had diverse clinical presentations and bacterial DNA profiles representing Gram-negative organisms (Table 2, Table 3, Fig. 1b). Patients admitted with gastrointestinal infections or trauma likely developed sepsis from gastrointestinal microbiota including known Gram-negative opportunistic pathogens [36]. The remaining patients within Group 2 with abscesses or airway infections had bacterial DNA OTUs that correlated to upper airway and skin associated microbiota [31, 33, 37–41]. The Group 3 bacterial DNA profiles were distinguished by the large proportion of Staphylococcus OTUs (Fig. 1). These samples were obtained from patients admitted for emergency surgical interventions, joint infections, and pneumonia (Table 2). Again, the role for Staphylococcus as a clinical pathogen in such presentations of sepsis is well documented [31, 37, 39, 42–50]. Taken together, these data support the interpretation of these bacterial DNA profiles as representation of bacterial bloodstream infections with DNA from known pathogenic organisms recovered that correlated to the patient’s clinical presentation at the time of enrollment in the study.

The molecular profiling results provided more evidence of sepsis bloodstream infection when compared to the conventional diagnostic blood culture. For the adult ICU blood samples included in the analysis, only 33% had a positive clinical blood culture (Table 2). In comparison, bacterial DNA was recovered from all these blood samples and the bacterial DNA profiles in these samples were distinct from those recovered from the blood of healthy adult control samples (Fig. 3). While the presence of bacterial DNA in these blood samples did not indicate the presence of viable organisms, it suggested that the clinical blood cultures were under-representing the presence of bloodstream infections in this cohort. These results are comparable to similar studies using molecular diagnostic platforms have also reported under representation of bloodstream infections when blood culture diagnostics were compared to PCR based methods [13, 51–55]. This study also outlined several cases where the bacterial DNA amplified from the blood sample had good concordance with bacterial pathogens that were recovered from pertinent clinical diagnostic cultures. Overall, combining our molecular profiling analysis of the bacterial DNA patterns with a chart review of the patient clinical data including culture-based diagnostic results strengthened our interpretations of the molecular profiling results and further demonstrated the potential for this molecular-based approach to augment culture-based microbial diagnostic results.

This study also demonstrated that the bacterial DNA patterns were conserved across various subsets of septic patients. Indeed, there was similar clustering of all the clinical blood samples regardless of the patient’s presentation to ICU or ED and across both adult and pediatric cohorts (Fig. 3). In addition, this analysis confirmed two principal bacterial DNA patterns seen in the septic ICU cohort; one in which Streptococcus DNA was the most prevalent and one in which Staphylococcus DNA was the most prevalent (Fig. 3). Further analysis of the OTU distribution of Streptococcus indicated that the principal predicted Streptococcus species found in whole blood were the Streptococcus Anginosus/Milleri Group and Streptococcus Mitis Group (S. pneumoniae/mitis/oralis) at 33.5 and 10.59% respectively (Additional file 3: Table S3). The prevalence of the Anginosus/Milleri Group superseding that of Mitis Group was not expected given many studies suggesting S. pneumoniae as a principal pathogen recovered in clinical diagnostic blood culture positive bloodstream infections [56]. A recent study indicated 89% of culture-positive bloodstream infections were a result of S. pneumoniae [57] whereas the Anginosus/Milleri Group represented a smaller proportion of the Streptococcus bloodstream infections [49]. As such, these results suggested greater diversity of Streptococcus species in sepsis bloodstream infections than previously considered based on blood culture diagnostics. Interestingly, other studies using targeted culturing and culture-independent approaches have also demonstrated a role for the Anginosus/Milleri Group in human infections [58–61]. This study now adds new data to suggest a greater role for this group in acute bloodstream infections than previously reported [8, 49, 57].

For Staphylococci, the OTU with sequence alignment to S. aureus represented 97% of the Staphylococcus OTUs present in the septic ICU population (Additional file 3: Table S3). Most reports from clinical diagnostic blood culture confirmed bloodstream infections indicate S. aureus as the second most commonly isolated organism [56]. S. aureus predominate blood samples were obtained from patients with documented surgical infections (11/17),
Staphylococcus respiratory infections (5/17), and septic arthritis (1/17). Post-operative *Staphylococcus* infections have been documented in other literature reports [62, 63] and *S. aureus* is a common pathogen in respiratory infections and septic joint infections [50]. The remaining 3% of *Staphylococcus* OTUs aligned with CoNS (Additional file 3: Table S3). Most population-based assessments cluster the CoNS bloodstream infections together since clinical laboratories don’t distinguish these organisms beyond this level [49, 64]. Taken together, the molecular profiling data suggested that there might be a larger role for diverse CoNS in sepsis than is currently appreciated using clinical diagnostic blood culture approaches.

Overall, this study demonstrated the potential strengths of the molecular profiling data when evaluated alongside the patient’s admissions data and, to some extent, their culture data. The results indicated *Streptococcus* and *Staphylococcus* as principal pathogens in sepsis bloodstream. However, the prevalence of polymicrobial DNA in whole blood from septic patients suggested there could be greater propensity for polymicrobial infections in sepsis than currently appreciated using cultivation-dependent and broth-enrichment based approaches. Similar results from direct blood analysis have shown utility of molecular profiling for identification of microbial DNA and its utility as an additional tool for sepsis diagnostics [13, 54, 55].

We recognize that our study had limitations. Not all the blood samples analyzed had a sequencing depth that allowed for good interpretation of β-diversity [65]. In the blood samples the amount of bacterial DNA template was low as compared to the host template resulting in the high relative abundance of the “noRoot” OTU. This “noRoot” OTU was attributed to the well-documented erroneous amplification of human DNA in clinical samples with universal 16S rRNA gene primers. This issue has been reported since the early days of PCR [66] and is still problematic in contemporary 16S rRNA gene studies [66–68]. In this study, the abundance of “noRoot” DNA often represented a large portion of the amplified sequences in whole blood. This was unique to our study and likely reflected the low ratio of bacterial to host DNA in these samples. It is difficult to know the exact concentration of bacteria in bloodstream infections since the blood culture results only indicate the CFU/ml of bacteria after a broth-enrichment. However, in the limited number of samples where culture from saponin treated whole blood was successful, the CFU/ml were between 1 to 30 (data not shown) suggesting the concentration of bacteria would be low in the clinical samples. Following the removal of the “noRoot” reads, the samples often had a low number of remaining sequences. A reasonable cut-off was needed to ensure that differences in the taxonomic structure of samples could be identified. The strength of UniFrac beta-diversity to identify meaningful patterns in various datasets has been well documented [27]. Even in small sample size simulations (50 sequences) the UniFrac values could be used to discriminate between samples [27]. However, when the expected similarity in microbial communities among different samples was anticipated to be high, more sequencing reads were required to identify relationships [27]. It is also known that between 500 and 1000 reads/sample is sufficient, but not ideal, to distinguish differences in phylogenetic composition between two samples using beta-diversity. As such, a depth of 500 reads was selected as it permitted evaluation of more of the samples with the knowledge that the interpretation of the profiles required caution in the absence of good clinical data. When compared to other molecular profiling studies of blood our abundance threshold was significantly lower [13]. Given the difference in DNA extraction protocols, PCR amplification, sequencing platforms and analysis methods it is difficult to compare the quality of sequencing data based on abundance per sample. Prior to extensive filtering the read per sample averaged at over 14,000 reads which is in line with other molecular profiling studies [13]. The lower abundance per sample was interpreted to reflect the low ratio of bacterial DNA sequences compared to the “noRoot” human DNA (Table 2). Since this was a ratio-based issue, the use of larger blood volumes was not predicted to circumvent these limitations. Nevertheless, the removal of these DNA sequences from the taxonomic profile enabled the analysis of the remaining, low proportion, bacterial DNA in the samples. Although this resulted in many samples not being fully analyzed, PCoA analysis indicated that low sequence depth samples still clustered alongside SB samples (Fig. 2). This would suggest that most whole blood samples had similar molecular profiles to the SB samples in Fig. 1 despite lower sequencing depth.

Another limitation was that the bacterial DNA profiles reflected relative not total DNA abundance. This meant that no conclusions the quantity of bacterial DNA in these samples. Attempts to quantify the bacterial load in the HB and SB samples, using RT-PCR, were unsuccessful due to the cross-reactivity of the 16S primers to human DNA in these samples (data not shown).

As such, the bacterial DNA profiles could indicate the taxonomic diversity in each sample but not the bacterial load. Finally, we reiterate that the molecular analysis identifies the presence of bacterial DNA not viable organisms. The isolation protocol described previously [9] should reduce the level of free DNA in the preparation and therefore these profiles should be enriched in DNA from intact cells.

Based on these limitations, it was essential that each sample was evaluated within the clinical context. Many
reviews of molecular profiling strategies have highlighted the importance of analyzing molecular data in conjunction with other clinical measures of severity (i.e., APACHE, SOFA scores), markers of infection (i.e., procalcitonin), and markers of inflammation (i.e., IL-6, IL-10) [69–72]. However, our findings reveal that when the bacterial DNA patterns were aligned with the clinical data it was apparent that meaningful patterns were observed in the data. Despite this, our data also highlighted discordance between blood culture enrichment and molecular sequencing can occur. When results were discordant, there was often other clinical data to support the molecular sequencing (Fig. 1a, Table 3). In other cases, the discordance was thought to result from difference in the time of collection as well as reflecting discrepancy between a broth enrichment method to that of direct sampling [69, 73–75]. While our initial blood samples were obtained within 24 h of ICU admission or in the ED once sepsis was suspected, it did not guarantee that our samples were collected prior to initiation of antimicrobial therapy. With early antibiotic therapy being a hallmark of sepsis management as outlined in sepsis guidelines, it was predicted that the majority of our ICU patient samples were obtained after antimicrobial therapy was started whereas blood culture results are often obtained prior to antimicrobial therapy [11, 76, 77]. As such, effective antimicrobial therapy was also considered when discordance was present.

Conclusions
The overall evaluation of a whole blood molecular profiling approach to evaluating septic bloodstream infections provided several novel findings. Overall, the bacterial DNA profiling of whole blood samples from adult and pediatric patients was correlated to a predicted bloodstream infection with either a viable organism or bacterial products in 75% of the samples analyzed in this study. In addition, the molecular profiling data predicted a greater role for polymicrobial infections in the pathogenesis of sepsis.

Additional files

**Additional file 1: Table S1.** OTUs identified as contamination and removed from OTU table. Outlines OTUs that were identified in the data as representing contamination and removed using custom perl scripts prior to final analysis of OTU distribution in each sample. (DOCX 12 kb)

**Additional file 2: Table S2.** ICU patient demographics and clinical markers of sepsis severity. This table includes summary statistics of patient data for samples from adult ICU patients. The data was separated by the beta-diversity groups identified in the meta-analysis. Data includes gender, age, illness severity scores, length of stay and outcomes. (DOCX 13 kb)

**Additional file 3: Table S3.** Streptococcus and Staphylococcus species predicted to be present in ICU patient blood samples. This table highlights the results of the DNA alignments of the 250 bp representative sequence from the Streptococcus and Staphylococcus OTUs identified in clinical blood samples to curated 16S rRNA sequence databases. (DOCX 13 kb)

**Abbreviations**
APACHE: Acute Physiology and Chronic Health Evaluation; ASN: Alberta Sepsis Network; CFU: Colony forming unit; CoNS: Coagulase-negative Staphylococci; ED: Emergency department; ICU: Intensive care unit; MRSA: Methicillin-resistant *Staphylococcus aureus*; OTU: Operational taxonomic unit; PCoA: Principal coordinates analysis; PCR: Polymerase chain reaction; SIRS: Systemic inflammatory response syndrome; SOFA: Sepsis related organ failure assessment; UPGMA: Unweighted pair group method with arithmetic mean

**Acknowledgements**
We thank the manager and co-ordinator of the CCEPTR resource, Joseé Wong, for her assistance with sample collection. We thank Dr. Dean Yergens for providing clinical data for this study. Special thanks to the research nurses and assistants who identified and enrolled patients with the ICU and ED at Foothills Medical Centre and the Alberta Children’s Hospital, Calgary, Canada.

**Funding**
This research was supported by a five year (2009–2014) Alberta Heritage Foundation for Medical Research (now known as Alberta Innovates) inter-disciplinary team grant. This grant supported the formation of the Alberta Sepsis Network. Project leads included: Drs. Chip Doig, Paul Kubes, and Ari Joffe. Drs. Michael Surette and John Conly were co-investigators. The Alberta Sepsis Network facilitated access to clinical samples and clinical data collection for this study. Design of the study and analysis of the data was done without any involvement from the Alberta Sepsis Network. Dr. Faria received stipend support for this research through the Alberta Sepsis Network grant funding. Alberta Innovates did not have a role in the design of the study, collection of samples, interpretation of the data, or in the preparation of the manuscript.

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**
MMPF carried out all the studies and drafted the manuscript. BW provided access to clinical samples through CCEPTR and contributed to revisions of this manuscript. MGS conceived of the study and performed the molecular sequencing analysis. JMC contributed to the coordination of the study and helped draft the manuscript. All authors read and approved of the final manuscript.

**Ethics approval and consent to participate**
Approval for this study was obtained from the Conjoint Health Research Ethics Board of the University of Calgary. All human samples were collected following the guidelines outlined in the Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement for the “Ethical Conduct for Research Involving Humans” dated December 2010. Human blood samples were collected as part of the Critical Care Epidemiologic and Biologic Tissue Resource (CCEPTR). Approval for CCEPTR was granted by the Conjoint Health Research Ethics Board of the University of Calgary with the Ethics ID for the study E-22236 on April 7, 2009. Informed written consent was obtained from all patients or their substitute decision maker prior to collecting samples. Substitute decision makers provided written consent when the patient was not able to provide consent due to altered level of consciousness or physical impairment. For patients considered as minors, under the age of 18, a legal guardian or parent provided written consent.

**Consent for publication**
Not applicable to this manuscript.

**Competing interests**
The authors declare that they have no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. 2Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. 3Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. 4Department of Critical Care, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. 5Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB T2N 4N1, Canada. 6O’Brien Institute for Public Health, University of Calgary, Calgary, AB T2N 4N1, Canada. 7Foothills Medical Centre, Alberta Health Services, Room AGW5, 1403 29th Street NW, Calgary, AB T2N 2T9, Canada.

Received: 13 August 2017 Accepted: 27 June 2018
Published online: 25 July 2018

References
1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Silbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55.
2. Diekema DJ, Beekman SE, Chapin KC, Morel KA, Munson E, Doern GV. Bacteremia and sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French bacteremia-sepsis study group. Am J Respir Crit Care Med. 1996;154(3 Pt 1):617–24.
3. Pittet D, Theveant B, Wenzel RP, Li N, Auckenthaler R, Suter PM. Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU effective distance metric for microbial community comparison. The ISME journal. 2015;9(4):943–9.
4. Valles J. Bacteremias in intensive care. Enferm Infecc Microbiol Clin. 1997;15(3):141–73.
5. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Spotorno S, Monneret V, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.
6. Doyle JS, Buisin KL, Thursky KA, Worth LI, Richards MJ. Epidemiology of infections acquired in intensive care units. Semin Respir Crit Care Med. 2011;32(2):115–38.
7. Gosiewski T, Ludwig-Galezowska AH, Hurninska K, Sroka-Oleskia A, Radkowsk P, Salamon D, Wojciechowicz J, Kus-Slowinska M, Bulanda M, Wolkow PP. Comprehensive detection and identification of bacterial DNA in the blood of patients with sepsis and healthy volunteers using next-generation sequencing method - the observation of DNAemia. Eur J Clin Microbiol Infect Dis. 2017;36(2):329–36.
DNA load in blood as a marker of infection in patients with community-acquired pneumonia. J Clin Microbiol. 2009;47(10):3308–12.

36. Snell J, Timmerman HM, Klareebzein M. The human intestine microbiome in health and disease an emerging diagnostic and therapeutic target. Agro Food Ind Hi Tec. 2011;22(2):222–4.

37. Laupland KB, Gregson DR, Flemmons WW, Hawkins D, Ross T, Church DL. Burden of community-onset bloodstream infection: a population-based assessment. Epidemiol Infect. 2007;135(6):1037–42.

38. Seifert H. The clinical importance of microbial findings in the diagnosis and management of bloodstream infections. Clin Infect Dis. 2009;48(Suppl 4):S238–45.

39. Custovic A, Smajlovic J, Hadzic S, Ahmetagic S, Tihic N, Hadzagic H. Epidemiological surveillance of bacterial nosocomial infections in the surgical intensive care unit. Matter socio-medica. 2011;46(1):17–11.

40. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome medicine. 2011;3(3):14.

41. Lyte M, Vlachoula N, Brown DR. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res. 2011;343(3):123–32.

42. Wolcott RD, Gontcharova V, Sun Y, Zischka A, Dowd SE. Bacterial diversity in surgical site infections: not just aerobic cocci any more. J Wound Care. 2009;18(8):317–23.

43. Erdem I, Ozgultekin A, Sengoz Inan A, Ozturk Engin D, Senbayrak Akcay S, Turan G, Dincer E, Oguzoglu N, Goktas P. Bloodstream infections in a medical-surgical intensive care unit: incidence, aetiology, antimicrobial resistance patterns of gram-positive and gram-negative bacteria. Clin Microbiol Infect. 2009;15(10):943–6.

44. Laupland KB, Lyurtikanen O, Sogaard M, Kennedy KJ, Orstedgaard J, Galbraith JC, Valiquette L, Jacobsson G, Collignon P, et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect. 2013;19(5):465–71.

45. Kumar S, Wang L, Fan J, Kraft A, Bose ME, Tiwari S, Van Dyke M, Haigis R, Laupland KB, Gregson DB, Flemons WW, Hawkins D, Ross T, Church DL. Severe community-onset bloodstream infections: a heterogeneous cohort of patients with signs of infective systemic inflammatory response syndrome. Shock. 2014;42(2):186–92.

46. Ziegler I, Josefson P, Ocken P, Molling P, Stralin K. Quantitative data from the SeptFast real-time PCR is associated with disease severity in patients with sepsis. BMC Infect Dis. 2014;14:155.

47. Moore MS, McCarrill MG, McCann CD, May L, Younes N, Jordan JA. Direct screening of blood by PCR and pyrosequencing for a 16S rRNA gene target from emergency department and intensive care unit patients being evaluated for bloodstream infection. J Clin Microbiol. 2016;54(1):199–105.

48. O’Dwyer MJ, Starczewski MH, Schrenzel J, Zacharowski K, Ecker DJ, Sampath R, Bealey D, Singer M, Libert N, Wilks M, et al. The detection of microbial DNA but not cultured bacteria is associated with increased mortality in patients with suspected sepsis-a prospective multi-Centre European observational study. Clin Microbiol Infect. 2017;23(3):e206–13.

49. Sibley CD, Peirano G, Church DL. Molecular methods for pathogen and microbial community detection and characterization: current and potential application in diagnostic microbiology. Infect Genet Evol. 2012;12(3):505–21.

50. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia –detection. J Clin Microbiol. 2008;46(9):3063.

51. Burdino E, Ruggiero T, Allice T, Milia MG, Gregori G, Milano R, Cerutti F, De Ronco P, et al. Comparative evaluation of the Vitek-2 compact and phoenix systems for rapid identification and antibiotic susceptibility testing directly from blood cultures of gram-negative and gram-positive isolates. Diagn Microbiol Infect Dis. 2012;72(2):210–31.

52. Hughes JB, Hellmann J, Ricketts TH, Bohannan BJM. Counting the uncountable: statistical approaches to estimating microbial diversity. Appl Environ Microbiol. 2001;67(10):4399–406.

53. Edwards U, Rogall T, Blocker H, Emde M, Bottger EC. Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res. 1989;17(19):7843–53.

54. Kommedal O, Simmon K, Karaca D, Langeland N, Wiker HG. Dual priming oligonucleotides for broad-range amplification of the bacterial 16S rRNA gene directly from human clinical specimens. J Clin Microbiol. 2012;50(4):1289–94.

55. Boey J, Wong J, Ong GB. Bacteria and septic complications in patients with perforated duodenal ulcers. Am J Surg. 1982;143(5):635–9.

56. Kim HK, Missiakas D, Schneewind O. Mouse models for infectious diseases caused by Staphylococcus aureus. J Immunol Methods. 2014;410:88–99.

57. Gherardi G, Angeletti S, Paniti M, Pompilio A, Di Bonaventura C, Crea F, Avola A, Fico L, Palazzo C, Sapia GF, et al. Comparative evaluation of the Vitek-2 compact and phoenix systems for rapid identification and antibiotic susceptibility testing directly from blood cultures of gram-negative and gram-positive isolates. Diagn Microbiol Infect Dis. 2012;72(2):210–31.

58. Kellner JD, Vanderkooi OG, MacDonald J, Gregson JC, Gregson DR, Robin HR, Surette MG. McKay agar enables routine quantification of ‘Streptococcus milleri’ group in cystic fibrosis patients. J Med Microbiol. 2010;59(Pt 5):534–40.

59. Seifert H, Grinnis ME, Field TR, Parkinson MD, Norgard JC, Gregson DR, Robin HR, Surette MG. McKay agar enables routine quantification of ‘Streptococcus milleri’ group in cystic fibrosis patients. J Med Microbiol. 2010;59(Pt 5):534–40.

60. Edwards U, Rogall T, Blocker H, Emde M, Bottger EC. Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res. 1989;17(19):7843–53.

61. Kommedal O, Simmon K, Karaca D, Langeland N, Wiker HG. Dual priming oligonucleotides for broad-range amplification of the bacterial 16S rRNA gene directly from human clinical specimens. J Clin Microbiol. 2012;50(4):1289–94.

62. Boey J, Wong J, Ong GB. Bacteria and septic complications in patients with perforated duodenal ulcers. Am J Surg. 1982;143(5):635–9.

63. Kim HK, Missiakas D, Schneewind O. Mouse models for infectious diseases caused by Staphylococcus aureus. J Immunol Methods. 2014;410:88–99.

64. Gherardi G, Angeletti S, Paniti M, Pompilio A, Di Bonaventura C, Crea F, Avola A, Fico L, Palazzo C, Sapia GF, et al. Comparative evaluation of the Vitek-2 compact and phoenix systems for rapid identification and antibiotic susceptibility testing directly from blood cultures of gram-negative and gram-positive isolates. Diagn Microbiol Infect Dis. 2012;72(2):210–31.

65. Hughes JB, Hellmann J, Ricketts TH, Bohannan BJM. Counting the uncountable: statistical approaches to estimating microbial diversity. Appl Environ Microbiol. 2001;67(10):4399–406.

66. Edwards U, Rogall T, Blocker H, Emde M, Bottger EC. Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res. 1989;17(19):7843–53.

67. Kommedal O, Simmon K, Karaca D, Langeland N, Wiker HG. Dual priming oligonucleotides for broad-range amplification of the bacterial 16S rRNA gene directly from human clinical specimens. J Clin Microbiol. 2012;50(4):1289–94.